RedHill Biopharma Limited
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, RedHill Biopharma Limited sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
RedHill Biopharma Limited: 13 sponsored US clinical trials, none currently recruiting.
RedHill Biopharma Limited sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 6 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cholangiocarcinoma, Extrahepatic, with 1 trials.
Top-decile sponsor footprint
RedHill Biopharma Limited ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
13 total, page 1 of 1
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
NCT04723537
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
NCT04616924
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
NCT04467840
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
NCT04414618
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
NCT03377179
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
NCT03198507
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
NCT03009396
ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
NCT02757326
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
NCT02757105
BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
NCT02246439
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
NCT01980095
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
NCT01951326
ABC294640 in Treating Patients With Advanced Solid Tumors
NCT01488513
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 6 |
How the RedHill Biopharma Limited archive is shaped
13 indexed studies, none listed as recruiting (0% open); 10 completed (77%).
Phase mix: 6 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Cholangiocarcinoma, Extrahepatic (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
RedHill Biopharma Limited: archived-pipeline peers nationwide
Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
RedHill Biopharma Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 archived trials
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this RedHill Biopharma Limited page
13 registered trials is a research-attention snapshot, not an endorsement of RedHill Biopharma Limited or any single study.
- None of RedHill Biopharma Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cholangiocarcinoma, Extrahepatic is the condition RedHill Biopharma Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cholangiocarcinoma, Extrahepatic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. RedHill Biopharma Limited pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.